Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 19;56(5):2001679.
doi: 10.1183/13993003.01679-2020. Print 2020 Nov.

Hiatus hernia and interstitial lung abnormalities

Peter M George  1   2 , Tomoyuki Hida  3 , Rachel K Putman  3 , Takuya Hino  3 , Sujal R Desai  4   2 , Anand Devaraj  4   2 , Sacheen Kumar  5 , John A Mackintosh  6 , Vilmundur Gudnason  7   8 , Hiroto Hatabu  3 , Gunnar Gudmundsson  8   9 , Gary M Hunninghake  3
Affiliations

Hiatus hernia and interstitial lung abnormalities

Peter M George et al. Eur Respir J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: P.M. George reports personal fees from Roche Pharmaceuticals and Teva, grants and personal fees from Boehringer Ingelheim, outside the submitted work. Conflict of interest: T. Hida has nothing to disclose. Conflict of interest: R.K. Putman reports grants from NIH, during the conduct of the study. Conflict of interest: T. Hino has nothing to disclose. Conflict of interest: S.R. Desai has nothing to disclose. Conflict of interest: A. Devaraj reports personal fees from Boehringer Ingelheim, Galapagos, Galecto Biotech and GSK, outside the submitted work. Conflict of interest: S. Kumar has nothing to disclose. Conflict of interest: J.A. Mackintosh reports personal fees for lectures from Roche, outside the submitted work. Conflict of interest: V. Gudnason has nothing to disclose. Conflict of interest: H. Hatabu reports grants from Canon Medical System Inc. and Konica-Minolta Inc., personal fees for consultancy from Mitsubishi Chemical Inc., and has been member of an advisory board for Canon Medical System Inc., outside the submitted work. Conflict of interest: G. Gudmundsson has nothing to disclose. Conflict of interest: G.M. Hunninghake reports personal fees from Boehringer Ingelheim, Mitsubishi Chemical and Gerson Lehrman Group, outside the submitted work.

Figures

FIGURE 1
FIGURE 1
Hiatus hernia and interstitial lung abnormality (ILA) classification. Graphical representation of a) normal thoracoabdominal anatomy (no hiatus hernia), b) grade I hiatus hernia and c) grades II–IV hiatus hernia. Mediastinal and lung windows from axial chest computed tomography scans demonstrate hiatus hernia anatomy and parenchymal involvement respectively for participants with and without ILA (A–F). Participant A has no hiatus hernia and no ILA. Participant B has no hiatus hernia and subpleural ILA with fibrosis. Participant C has a grade I hiatus hernia and no ILA. Participant D has a grade I hiatus hernia and subpleural ILA without fibrosis. Participant E has a grade II–IV hiatus hernia and no ILA. Participant F has a grade II–IV hiatus hernia and subpleural ILA with fibrosis.
See this image and copyright information in PMC

References

    1. Noth I, Zangan SM, Soares RV, et al. Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis. Eur Respir J 2012; 39: 344–351. - PubMed
    1. Tossier C, Dupin C, Plantier L, et al. Hiatal hernia on thoracic computed tomography in pulmonary fibrosis. Eur Respir J 2016; 48: 833–842. - PubMed
    1. Mackintosh JA, Desai SR, Adamali H, et al. In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia is associated with disease progression and mortality. Eur Respir J 2019; 53: 1802412. - PubMed
    1. Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 2013; 1: 369–376. - PMC - PubMed
    1. Kreuter M, Wuyts W, Renzoni E, et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med 2016; 4: 381–389. - PubMed